REGENESANCE B V has a total of 28 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2007. It filed its patents most often in Australia, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are PECHER GABRIELE, JIANGSU RUNJIE BIOTECHNOLOGY CO LTD and POLYMUN SCIENT IMMUNBIO FORSCH.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 6 | |
#2 | United States | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Hong Kong | 3 | |
#5 | Canada | 2 | |
#6 | Hungary | 2 | |
#7 | WIPO (World Intellectual Property Organization) | 2 | |
#8 | China | 1 | |
#9 | Israel | 1 | |
#10 | Republic of Korea | 1 | |
#11 | Slovenia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Baas Frank | 27 |
#2 | Ramaglia Valeria | 11 |
#3 | Van Dijk Marc A | 9 |
#4 | Fluiter Kees | 6 |
Publication | Filing date | Title |
---|---|---|
AU2016202684A1 | Complement inhibition for improved nerve regeneration | |
WO2016118007A1 | Means and methods for counteracting complement-mediated hemolytic anemia | |
AU2015365583A1 | Antibodies that bind human C6 and uses thereof | |
AU2014280940A1 | Complement antagonists and uses thereof | |
AU2014200822A1 | Complement inhibition for improved nerve regeneration | |
HUE027169T2 | Complement antagonists and uses thereof | |
CA2980614A1 | Anti-sense oligonucleotide for use in facilitating axonal regeneration |